ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.44
-0.52%
US Tech 100
21,190.40
0.62%
S&P 500
6,051.09
0.00%
US Dollar vs CAD
1.42375
0.00%
Bitcoin
101,697.63
0.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Photocure Asa (0IMT)

  7. Photocure Asa (0IMT) News

0IMT

Photocure Asa (0IMT)

Photocure Asa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0IMT
DateTimeSourceHeadlineSymbolCompany
08/09/20231:30AMPR Newswire (US)Photocure ASA: Results for the second quarter and first half of 2023LSE:0IMTPhotocure Asa
08/09/20231:26AMPR Newswire (US)Photocure ASA: Results for the second quarter and first half of 2023LSE:0IMTPhotocure Asa
07/06/20233:57AMPR Newswire (US)Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in ChinaLSE:0IMTPhotocure Asa
07/06/20233:54AMPR Newswire (US)Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in ChinaLSE:0IMTPhotocure Asa
05/10/20231:18AMPR Newswire (US)Photocure ASA: Results for the first quarter of 2023LSE:0IMTPhotocure Asa
05/10/20231:15AMPR Newswire (US)Photocure ASA: Results for the first quarter of 2023LSE:0IMTPhotocure Asa
05/04/20236:48AMPR Newswire (US)Photocure ASA - Correction: Annual general meeting heldLSE:0IMTPhotocure Asa
05/04/20236:44AMPR Newswire (US)Photocure ASA - Correction: Annual general meeting heldLSE:0IMTPhotocure Asa
05/03/202311:58AMPR Newswire (US)Photocure ASA - Annual general meeting heldLSE:0IMTPhotocure Asa
05/03/202311:53AMPR Newswire (US)Photocure ASA - Annual general meeting heldLSE:0IMTPhotocure Asa
05/03/20234:53AMPR Newswire (US)Photocure ASA: Invitation to presentation of first quarter 2023 financial resultsLSE:0IMTPhotocure Asa
05/03/20234:52AMPR Newswire (US)Photocure ASA: Invitation to presentation of first quarter 2023 financial resultsLSE:0IMTPhotocure Asa
05/02/202310:35AMPR Newswire (US)Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light CystoscopyLSE:0IMTPhotocure Asa
05/02/202310:30AMPR Newswire (US)Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light CystoscopyLSE:0IMTPhotocure Asa
04/12/20239:14AMPR Newswire (US)Photocure ASA: Annual Report 2022LSE:0IMTPhotocure Asa
04/12/20239:14AMPR Newswire (US)Photocure ASA - Notice of the Annual General Meeting 3 May 2023LSE:0IMTPhotocure Asa
04/12/20239:12AMPR Newswire (US)Photocure ASA - Notice of the Annual General Meeting 3 May 2023LSE:0IMTPhotocure Asa
04/12/20239:11AMPR Newswire (US)Photocure ASA: Annual Report 2022LSE:0IMTPhotocure Asa
03/14/20232:53AMPR Newswire (US)Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancerLSE:0IMTPhotocure Asa
03/14/20232:40AMPR Newswire (US)Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancerLSE:0IMTPhotocure Asa
02/23/20231:29AMPR Newswire (US)Photocure ASA: Results for the fourth quarter of 2022LSE:0IMTPhotocure Asa
02/23/20231:27AMPR Newswire (US)Photocure ASA: Results for the fourth quarter of 2022LSE:0IMTPhotocure Asa
02/20/202312:43AMPR Newswire (US)Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLCLSE:0IMTPhotocure Asa
01/03/202312:47AMPR Newswire (US)New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursementLSE:0IMTPhotocure Asa
01/03/202312:45AMPR Newswire (US)New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursementLSE:0IMTPhotocure Asa
12/05/20221:08AMPR Newswire (US)New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO MeetingLSE:0IMTPhotocure Asa
12/05/20221:03AMPR Newswire (US)New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO MeetingLSE:0IMTPhotocure Asa
11/07/20221:11AMPR Newswire (US)Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance settingLSE:0IMTPhotocure Asa
11/02/20222:38AMPR Newswire (US)Photocure ASA: Results for the third quarter of 2022LSE:0IMTPhotocure Asa
11/02/20222:37AMPR Newswire (US)Photocure ASA: Results for the third quarter of 2022LSE:0IMTPhotocure Asa
 Showing the most relevant articles for your search:LSE:0IMT

Your Recent History

USOTC
WNFT
Worldwide NFT (PK)
NASDAQ
TNXP
Tonix Pharmaceuticals
USOTC
ICTY
Eyecity Com (PK)
USOTC
TGLO
TheGlobe com (PK)
USOTC
GTCH
GBT Technologies (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
CEOS
CeCors (PK)
USOTC
CGAC
Code Green Apparel (PK)
AMEX
BURU
Nuburu
USOTC
HIRU
Hiru (PK)
USOTC
LQMT
Liquidmetal Technologies (QB)
USOTC
NLST
Netlist (QB)
NASDAQ
AMRN
Amarin
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
NVDA
NVIDIA
NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved